ISMPP Launches the GenAI in Practice Survey Artificial Intelligence (AI) is rapidly transforming the way we approach medical communications, but how are ISMPP members really using AI today? Where is AI helping the most, what barriers remain, and what do members want...
You are a medical publication professional in a pharmaceutical company, working on a clinical trial publication for an investigational drug that has the potential to change clinical practice in the treatment of a life-threatening disease. Some of the authors are keen...
Rachel Jenkins, BSc, Taylor & Francis; Dawn Nicewarner, PhD, CMPP, Organon; Steve Palmisano, BSc, The Lockwood Group; Kelly Soady, PhD, CMPP, Oxford PharmaGenesis. Email your questions and comments on this article to TheMAP@ismpp.org. What Does Accessibility...
Jennifer Ghith, MS, MBA, GlaxoSmithKline; Matt Lewis, MPA, LLMental; Bob Schijvenaars, PhD, Digital Science; Monica Mody, PhD, Madrigal Pharmaceuticals; Andy Shepherd, PhD, CMPP, Envision Medical Communications; Valerie Moss, PhD, CMPP, Prime; Gary Lyons, Coronado...
Medical publication policies and guidelines offer a framework for best practices, but there may be situations when more than one approach seems reasonable. The primary purpose of “What Would You Do?” is to explore examples of such situations. With the limited...
